Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of NMD670 in Adult Patients with Type 1 and Type 2 Charcot-Marie-Tooth Disease
2023-507892-23-00Phase 2Completed
- Sponsor
- NMD Pharma
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in Charcot-Marie-Tooth disease type 1 (CMT1) and Charcot-Marie-Tooth disease type 2 (CMT2) comparing NMD670 with Placebo (2 arms). Primary endpoint: Change from baseline in 6-minute walk test distance at day 21. Started Aug 2024; status: completed.
02
Drugs
ignaseclant
03
Conditions
Charcot-Marie-Tooth disease type 1 (CMT1)Charcot-Marie-Tooth disease type 2 (CMT2)
Beyond the preview
Go deeper on 2023-507892-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507892-23-00.